GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

NCT01655628 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Stage IV Nasopharyngeal Carcinoma

Interventions

DRUG: GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)
DRUG: GC chemotherapy (Gemcitabine, Cisplatin)

Sponsor

Sun Yat-sen University